Dosimetric feasibility analysis and presentation of an isotoxic dose-escalated radiation therapy concept for glioblastoma used in the PRIDE trial (NOA-28; ARO-2022-12).
Bodensohn R, Fleischmann DF, Maier SH, Anagnostatou V, Garny S, Nitschmann A, Büttner M, Mücke J, Schönecker S, Unger K, Hoffmann E, Paulsen F, Thorwarth D, Holzgreve A, Albert NL, Corradini S, Tabatabai G, Belka C, Niyazi M.
Bodensohn R, et al. Among authors: thorwarth d.
Clin Transl Radiat Oncol. 2023 Dec 3;45:100706. doi: 10.1016/j.ctro.2023.100706. eCollection 2024 Mar.
Clin Transl Radiat Oncol. 2023.
PMID: 38116137
Free PMC article.